|
|
U.S. Arthritis Therapies MarketsPublished by: Frost & Sullivan Published: May. 25, 2004 Table of Contents1 EXECUTIVE SUMMARY Executive Summary Executive Summary 2 TOTAL U.S. ARTHRITIS THERAPIES MARKET Overview Introduction Methodology Market Overview and Definition Report Scope and Market Segmentation Scope and Segmentation Market Engineering Measurement Analysis for Total Market Market Demand and Forecasts Introduction Patient Forecasts Pricing Forecasts Revenue Forecasts Competitive Analysis Competitive Landscape Market Share Industry Issues and Challenges Frost and Sullivan Awards Company of the Year Award Technology Innovation Award Research and Development Excellence Award 3 BIOLOGICAL RESPONSE MODIFIERS ARTHRITIS THERAPIES MARKET Segment Highlights Segment Highlights Overview Introduction Biologic Response Modifier Market Engineering Measurement Analysis Segment Issues Market Demand and Forecasts Revenue Analysis and Market Size Market Trends Factors Affecting Market Growth Product Trends Pricing Trends Competitive Analysis Competitive Landscape Pipeline Analysis Market Share 4 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET Segment Highlights Segment Highlights Overview Introduction Non-Steroidal Anti-Inflammatory Drug Market Engineering Measurement Analysis Segment Issues Market Demand and Forecasts Revenue Analysis and Market Size Market Trends Factors Affecting Market Growth Product Trends I Product Trends II Pricing Trends Competitive Analysis Competitive Landscape Pipeline Analysis Market Share 5 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET Segment Highlights Segment Highlights Overview Introduction Disease Modifying Anti-Rheumatic Drug (DMARD) Arthritis Therapies Market Engineering Measurement Analysis Segment Issues Market Demand and Forecasts Revenue Analysis and Market Size Market Trends Factors Affecting Market Growth Product Trends Pricing Trends Competitive Analysis Competitive Landscape Pipeline Analysis Market Share 6 APPENDIX Decision Support Databases Arthritis Prevalence Population 55 and above Biotechnology Companies Hospital Beds Obese Population AbstractThe high price of biological response modifiers (BRMs) open exciting opportunities for arthritis drug manufacturers, while their exceptional clinical performance offers hope to millions suffering from the disease. Though profitable for manufacturers, the annual BRM treatment cost of over $10,000 proves prohibitive for most patients. However, with its ability to curb joint degeneration and restore normality in motion and functioning, most patients are willing to take on debts and mortgages in order to meet the high costs that most managed care plans refuse to cover. Significantly lower-priced disease-modifying anti-rheumatic drugs (DMARDs) are a viable alternative for arthritis patients, but fail to provide the numerous benefits of BRMs. DMARDs also come with several drawbacks such as higher toxicity caused by prolonged usage and the inability to reverse the effects of rheumatoid arthritis. Additionally, with the entry of lower-priced and improved drugs that offer convenient dosing and easier administration, prices of BRMs are likely to fall in order to meet the growing competition.
This research service analyzes the key drivers and challenges influencing the U.S. arthritis therapies market. Product and pricing trends coupled with patient and revenue forecasts enable participants to formulate a structured marketing plan. Product trends and pipeline analysis give an insight into future opportunities in various product segments such as BRMs, DMARDs, COX-2 inhibitors (COX-2s), and other non-steroidal anti-inflammatory drugs (NSAIDs). Market share and competitive analysis throw light on essential strategies to achieve success in the competitive arthritis therapies market.
|
|
|||
|
About MarketResearch.com
|
||||